ADPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adaptive Biotechnologies Corp (ADPT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company demonstrates promising growth potential and positive analyst sentiment, the financial performance shows significant losses, and technical indicators do not strongly support an immediate entry point. The lack of recent Intellectia Proprietary Trading Signals further diminishes the urgency to invest now. A 'hold' action is recommended until more favorable conditions arise.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 61.164, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 16.372), which could limit immediate upside potential.
Key growth drivers include EMR integrations, community adoption, and a shift to blood-based testing.
Despite revenue growth, the company posted a net income loss of -$13.58M in Q4 2025, with EPS declining by -60.87% YoY. The stock has a 60% chance of declining in the short term based on candlestick pattern analysis. No recent congress trading data or significant insider activity has been reported.
In Q4 2025, revenue increased by 51.04% YoY to $71.68M, and gross margin improved by 21.12% YoY to 73.98%. However, net income dropped by -59.70% YoY to -$13.58M, and EPS fell by -60.87% YoY to -0.09.
Analysts maintain a positive outlook, with multiple firms raising price targets to $21-$22 and reiterating Buy or Overweight ratings. Analysts highlight strong fundamentals and growth drivers, including new indications and pharma guidelines.
